None listed
Conditions
Interventions
Genetic : The pre-procedure assessment of patients, who have provided informed consent for the clinical trial, includes evaluating their condition. In addition to the ARU and PRU tests, which are clin
if immediate transport is not possible, the sample should be refrigerated until testing. DNA sequencing is performed according to the diagnostic guidelines of the hospital's Department of Laboratory M
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Adult women and men aged 19 to under 75 years - Individuals planning to undergo stent-assisted coil embolization for unruptured cerebral aneurysms who are taking antiplatelet agents before the procedure and have undergone platelet function testing - Modified Rankin Scale (mRS) score = 2 at screening - Individuals who have received a full explanation of the study and have provided final consent to participate
Exclusion criteria
Exclusion criteria: - Individuals with neurological deficits at the time of aneurysm treatment (modified Rankin Scale score of 3 or higher) making it impossible to assess complications - Individuals with known allergic reactions to aspirin or clopidogrel - Individuals at high risk of excessive bleeding due to conditions such as intracranial hemorrhage or severe gastric ulcers - Individuals with a bleeding tendency or coagulation disorders - Individuals deemed at high risk for embolic stroke by the investigator, such as those with atrial fibrillation requiring dual antiplatelet or anticoagulant therapy, extracranial or intracranial vessel occlusion or stenosis greater than 70%, moyamoya disease, or cerebrovascular malformations - Individuals with other intracranial conditions (e.g., brain tumors, moyamoya disease, cerebrovascular malformations) - Individuals with uncontrolled heart failure or angina - Individuals with malignant tumors requiring treatment - Pregnant women, women who might be pregnant, and breastfeeding women - Individuals who are unconscious at the time of diagnosis - Individuals with thrombocytopenia ( 100 IU/L) - Individuals with renal disease (creatinine > 2 mg/dL or eGFR < 30 ml/min/1.73m²) - Individuals unable to comply with regular follow-up - Individuals with poor medication adherence for various reasons - Individuals with psychiatric disorders - Individuals with a medical condition indicating a life expectancy of less than two years - Any other individuals deemed unsuitable for clinical trial participation by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CYP2C19 DNA sequencing | — |
Secondary
| Measure | Time frame |
|---|---|
| ARU(Aspirin Response Unit), PRU(P2Y12 Reaction Unit) | — |
Countries
Korea, Republic of
Contacts
Public ContactMinwoo Kim
Asan Medical Center
Outcome results
None listed